TEVA TEV-408 Hits Primary Endpoint in Celiac Phase 2a

Teva (TEVA) reported positive Phase 2a topline results on September 2 for TEV-408, an in-house anti-IL-15 antibody, in celiac disease. The trial met its primary endpoint, showing statistically significant prevention of gluten-induced intestinal damage versus placebo at week 8. Shares rose about 3.6% to $37.49.

The primary endpoint was villous height-to-crypt depth (Vh:Cd) ratio, a measure of how intact the intestinal lining is. The least-squares mean change from baseline was -0.43 for a single subcutaneous dose of TEV-408 versus -0.88 for placebo, a treatment difference of 0.45 (95% CI 0.06 to 0.84, p<0.05).

TEV-408 is a monoclonal antibody that binds and neutralizes interleukin-15, a cytokine that drives the immune attack on the intestinal lining when someone with celiac disease eats gluten. Blocking IL-15 is meant to let the gut heal rather than just manage symptoms, which is why the Vh:Cd architecture measure is the right early readout.

Celiac disease affects roughly 1% of the population, about three million people in the US, and there is no FDA-approved drug for it. The standard of care is a lifelong gluten-free diet, which fails to fully heal the gut in a meaningful share of patients.

The readout validates Teva’s “pipeline-in-a-product” strategy: proof that its internal biologics engine, not just licensed assets, can produce clinical wins as the generics giant pivots toward innovative medicine. For how to judge the numbers, see the guide on reading a clinical trial press release.

The strategic stake is bigger than one drug. Teva is best known as a generics maker, and its pivot to branded biologics has drawn skepticism. A homegrown antibody clearing its first efficacy hurdle gives management a concrete data point that the internal pipeline, not just partnered assets, can carry the growth story as the generics base matures.

The caveat is material. This is a small Phase 2a study with a biomarker surrogate as the primary endpoint, not a symptom measure, and celiac disease has a long graveyard: Amgen’s AMG 714, Takeda’s TAK-062, and 9 Meters all failed or stalled on IL-15 and related targets. The real test is whether Teva can convert a surrogate hit into a Phase 2b or 3 study with histologic and symptom endpoints plus durable benefit.

Watch for the next step: Phase 2b/3 planning and dosing details. A clean primary-endpoint hit in a zero-competition, high-prevalence indication is genuinely newsworthy for a stock most investors price as a generics cash-flow story.

Source: Teva Phase 2a topline results press release